SanBio Company Limited Logo

SanBio Company Limited

Developing regenerative cell therapies for severe neurological disorders like brain injury and stroke.

4592 | T

Overview

Corporate Details

ISIN(s):
JP3336750009
LEI:
Country:
Japan
Address:
中央区明石町8番1号
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

SanBio Company Limited is a biotechnology firm dedicated to the research, development, production, and commercialization of regenerative cell medicines. The company focuses on creating novel treatments for severe neurological disorders, aiming to restore functions lost due to injury or disease. Its primary pipeline targets conditions affecting the central nervous system, such as chronic motor deficits resulting from traumatic brain injury and stroke. SanBio's lead product candidate, SB623 (marketed in Japan as AKUUGO®), is an allogeneic cell therapy developed to improve motor function in patients. The company leverages its proprietary technology for large-scale production to address significant unmet medical needs in neurology.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-07 01:00
Share Issue/Capital Change
訂正臨時報告書
Japanese 31.2 KB
2025-09-12 08:31
Regulatory Filings
確認書
Japanese 7.9 KB
2025-09-12 08:31
Interim / Quarterly Report
半期報告書-第13期(2025/02/01-2026/01/31)
Japanese 230.6 KB
2025-06-13 08:45
Regulatory Filings
臨時報告書
Japanese 19.2 KB
2025-04-24 08:31
AGM Information
臨時報告書
Japanese 23.7 KB
2025-04-23 08:31
Registration Form
確認書
Japanese 8.0 KB
2025-04-23 08:31
Governance Information
内部統制報告書-第12期(2024/02/01-2025/01/31)
Japanese 21.6 KB
2025-04-23 08:30
Annual Report
有価証券報告書-第12期(2024/02/01-2025/01/31)
Japanese 1.3 MB
2025-03-17 07:30
Earnings Release
臨時報告書
Japanese 21.2 KB
2025-02-14 07:30
Registration Form
有価証券届出書(参照方式)
Japanese 168.5 KB
2024-12-25 07:30
Regulatory Filings
臨時報告書
Japanese 19.3 KB
2024-12-02 07:30
Registration Form
有価証券届出書(参照方式)
Japanese 112.5 KB
2024-09-17 08:02
Regulatory Filings
臨時報告書
Japanese 19.0 KB
2024-09-17 08:01
Report Publication Announcement
確認書
Japanese 7.9 KB
2024-09-17 08:01
Interim / Quarterly Report
半期報告書-第12期(2024/02/01-2024/07/31)
Japanese 181.0 KB

Automate Your Workflow. Get a real-time feed of all SanBio Company Limited filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for SanBio Company Limited

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for SanBio Company Limited via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Developing nanomedicines and drug delivery systems for oncology, hematology, and diagnostics.
Malaysia
N/A
Metagenomi, Inc. Logo
Discovering novel gene editing tools from nature for curative genetic medicines.
United States of America
MGX
MindWalk Holdings Corp. Logo
AI-powered biotherapeutics firm offering end-to-end antibody discovery and engineering services.
United States of America
HYFT
Mips Logo
Licenses patented helmet technology to reduce rotational impact injuries in sports and construction.
Sweden
MIPS
A think tank providing research, consulting, and ICT solutions to public & private sectors.
Japan
3636
Modus Therapeutics Holding AB Logo
Developing sevuparin, a polysaccharide for sepsis, septic shock, and chronic inflammation.
Sweden
MODTX
Molecure S.A. Logo
Develops first-in-class small molecule drugs for oncology and inflammatory/fibrotic diseases.
Poland
MOC
Monopar Therapeutics Logo
Clinical-stage biotech developing radiopharmaceuticals for oncology and therapies for rare diseases.
United States of America
MNPR
Mural Oncology PLC Logo
Clinical-stage company developing cytokine immunotherapies for hard-to-treat solid tumors.
Ireland
MURA
N4 PHARMA PLC Logo
Developing a nanoparticle delivery system for advanced gene and vaccine therapies.
United Kingdom
N4P

Talk to a Data Expert

Have a question? We'll get back to you promptly.